Coriell Life Sciences

First-of-its-Kind Personalized 'COVID-19 Risk Score' Launches to Enable Safer Re-opening and Return to Work Plans

Coriell Life Sciences’ advanced data analytics examine individuals’ health history to identify those who are more likely to have severe or fatal outcomes if infected with novel coronavirus.
1-Jun-2020 9:00 AM EDT, by Coriell Life Sciences

Newswise — As more businesses and employees prepare to return to work around the country, Coriell Life Sciences (CLS) is rolling out a new tool in the fight against COVID-19: personalized COVID-19 Risk Scores.  Using proprietary, advanced data analytics, CLS analyzes information from medical records to identify the number of unique risk factors linked to poor COVID-19 outcomes an individual has.  Factors include thousands of potential risk elevators, from cardiovascular disease, diabetes and hypertension to allergies, anemia, and more.  The higher the number of risk factors, the higher the likelihood of experiencing severe or fatal symptoms if infected with the virus.

“This type of intelligence has the power to play a pivotal role in protecting the most vulnerable among us,” says Jeffrey A. Shaman, PhD, Chief Science Officer at Coriell Life Sciences.  “It’s clear people who suffer from chronic medical conditions are far more likely to fare poorly if they have COVID-19, but it’s hardly that simple.  Other factors, such as blood type and medications used, are also showing evidence they may be related to negative outcomes.  By analyzing individuals’ health history against thousands of medical codes that are aligned to risk factors for poor COVID-19 outcomes, we can determine who has the greatest risk of requiring acute care and empower them to be more vigilant in protecting their health.”

Individuals are eligible for COVID-19 risk scoring through participating employers.   

“Beyond empowering individuals to better protect their health, this information can also be used to help business leaders strategically tackle the high-stakes complexities surrounding when and how to get their teams back to work safely,” notes Coriell Life Sciences’ President & CEO Scott Megill.  “Both are critical elements in lessening the impact of this pandemic on public health and our country’s economic health.  The bottom line is we must make better use of the information that’s available today while the global scientific community remains keenly focused on scaling diagnostics and developing effective therapeutics and a viable vaccine.”

COVID-19 risk scoring is part of CLS’ new Return to Work Program.  This program provides an intelligence-driven solution designed to help organizations safely resume operations.  In addition to analyzing employee and facility data to illuminate risks and barriers to re-opening, the program offers businesses turnkey infrastructure for managing large-scale COVID-19 testing of employees in partnership with a network of laboratories across the country.

A leader in genetic science, CLS also enables organizations to help employees advocate for their health by offering personalized COVID-19 Genetic Drug Safety Reports.  Based on preemptive DNA testing, this report reveals how an individual would likely respond to approximately 45 drugs that could be used during COVID-19 treatment and have known genetic implications.  This information can be provided to a physician or pharmacist to inform an effective treatment plan.

“The reality is that some drugs just don’t work for some people,” notes Dr. Shaman.  “Some aren’t safe for one person but are completely fine for another.  Differences in our DNA are responsible for some of this variation.  Precision medicine enables us to determine which drugs will be both safe and effective for patients with COVID-19 – as well as many other conditions.” 

To learn more, visit coriell.com.

 

About Coriell Life Sciences

Coriell Life Sciences (CLS), a leader in genetic science, uses innovation in precision medicine to reduce healthcare costs and empower a healthier world.  With scientific expertise that spans six decades, CLS bridges the gap between genetic knowledge and clinical application and offers the most comprehensive medication risk management program on the market.  Visit coriell.com, email info@coriell.com or follow @CoriellLife.

# # #




Filters close

Showing results

110 of 2445
Released: 2-Jul-2020 8:50 AM EDT
Learn from the pandemic to prevent environmental catastrophe, scientists argue
University of Cambridge

• COVID-19 is comparable to climate and extinction emergencies, say scientists from the UK and US – all share features such as lagged impacts, feedback loops, and complex dynamics. • Delayed action in the pandemic cost lives and economic growth, just as it will with environmental crises – but on a scale “too grave to contemplate”.

Released: 1-Jul-2020 5:30 PM EDT
COVID-19 seed grants awarded to 7 ISU research projects
Iowa State University

Iowa State's COVID-19 Research Seed Grant program will support the initial stages of high-risk/high-reward projects that address the COVID-19 crisis.

Released: 1-Jul-2020 4:30 PM EDT
National Survey on COVID-19 Pandemic Shows Significant Mental Health Impact
Beth Israel Deaconess Medical Center

The findings of a nationwide survey assessing the effects of the COVID-19 pandemic on the emotional wellbeing of U.S. adults show 90 percent of survey respondents reported experiencing emotional distress related to the pandemic.

Released: 1-Jul-2020 2:40 PM EDT
Surveys Reveal Significant Shifts in Consumer Behavior During Pandemic
Rensselaer Polytechnic Institute (RPI)

The COVID-19 pandemic has significantly altered how people shop, how much they buy, the trips they take outside their homes, and the number of tele-activities — like work, medicine, and education — that have become commonplace. These changes were rapid and have tremendously impacted the economy, supply chains, and the environment. Two sets of surveys were conducted by researchers at Rensselaer Polytechnic Institute in an effort to quantify and understand these unprecedented shifts — and evaluate the likelihood they may last after the pandemic has ended.

Released: 1-Jul-2020 2:20 PM EDT
COVID-19 Fatality Risk Is Double Earlier Estimates: Study
Columbia University, Mailman School of Public Health

In one of the most robust studies of COVID-19 mortality risk in the United States, researchers estimate an infection fatality rate more than double estimates from other countries, with the greatest risk to older adults. Columbia University Mailman School of Public Health scientists and New York City Department of Health and Mental Hygiene colleagues published the findings on the pre-print server medRxiv ahead of peer review.

Released: 1-Jul-2020 2:15 PM EDT
Study Examines Limiting School Capacity for New York City Reopening
Columbia University, Mailman School of Public Health

Data modeling projections by Columbia University Mailman School of Public Health scientists evaluate potential policies to reduce new infections, hospitalizations, and deaths in coming months, including by limiting school capacity by 50 percent or capping capacity of certain industries to 25 percent during Phase Four, as well as by implementing an “adaptive PAUSE” system to re-implement social distancing rules during a rebound. The researchers have been working with the New York City Department of Health and Mental Hygiene on COVID-19 planning. Their new report is posted on Github.

Released: 1-Jul-2020 12:55 PM EDT
Study: Identifying Optimal Points of Intervention to Address Racial and Ethnic Disparities in COVID-19 Fatality Rates in New York State
University at Albany, State University of New York

Results from a new COVID-19 epidemiological study have been released from the University at Albany in partnership with the New York State Department of Health (NYSDOH); the findings were published today in the peer-reviewed journal, Annals of Epidemiology.

Newswise: 236360_web.jpg
Released: 1-Jul-2020 12:40 PM EDT
Clinical-grade wearables offer continuous monitoring for COVID-19
Northwestern University

Stamp-sized device comprises a suite of clinical-grade sensors, including temperature and pulse oximetry


Showing results

110 of 2445

close
0.79544